Join
Live feed
·
PRReleasevia Quantisnow
Affimed N.V. logo

Affimed Announces 100% Objective Response Rate at Highest Dose in Phase 1-2 Study of Cord Blood-derived Natural Killer Cells Pre-complexed with Innate Cell Engager AFM13 for CD30-positive Lymphomas

ByQuantisnow·Wall Street's wire, on your screen.
AFMD· Affimed N.V.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track AFMD (Affimed N.V.) and more on Quantisnow.